$HGEN $GILD Big Effect Trial with Remdesivir! WOW! Biological: Lenzilumab Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity. Drug: Remdesivir Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. clinicaltrials.gov/ct2/show...
  • 1
1 Like